2014 Q2 Form 10-Q Financial Statement
#000119312514325391 Filed on August 28, 2014
Income Statement
Concept | 2014 Q2 | 2013 Q2 |
---|---|---|
Revenue | $6.776M | $5.457M |
YoY Change | 24.17% | |
Cost Of Revenue | $2.403M | $2.119M |
YoY Change | 13.4% | |
Gross Profit | $4.373M | $3.338M |
YoY Change | 31.01% | |
Gross Profit Margin | 64.54% | 61.17% |
Selling, General & Admin | $3.926M | $2.748M |
YoY Change | 42.87% | |
% of Gross Profit | 89.78% | 82.32% |
Research & Development | $792.0K | $846.0K |
YoY Change | -6.38% | |
% of Gross Profit | 18.11% | 25.34% |
Depreciation & Amortization | $110.0K | $170.0K |
YoY Change | -35.29% | |
% of Gross Profit | 2.52% | 5.09% |
Operating Expenses | $7.121M | $5.713M |
YoY Change | 24.65% | |
Operating Profit | -$345.0K | -$256.0K |
YoY Change | 34.77% | |
Interest Expense | -$640.0K | -$540.0K |
YoY Change | 18.52% | |
% of Operating Profit | ||
Other Income/Expense, Net | $366.0K | -$5.000K |
YoY Change | -7420.0% | |
Pretax Income | -$623.0K | -$802.0K |
YoY Change | -22.32% | |
Income Tax | -$1.500M | $0.00 |
% Of Pretax Income | ||
Net Earnings | $877.0K | -$802.0K |
YoY Change | -209.35% | |
Net Earnings / Revenue | 12.94% | -14.7% |
Basic Earnings Per Share | $0.87 | -$0.79 |
Diluted Earnings Per Share | $0.13 | -$0.79 |
COMMON SHARES | ||
Basic Shares Outstanding | 1.013M | 1.011M shares |
Diluted Shares Outstanding | 6.940M | 1.011M shares |
Balance Sheet
Concept | 2014 Q2 | 2013 Q2 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $7.900M | |
YoY Change | ||
Cash & Equivalents | $7.872M | $4.485M |
Short-Term Investments | ||
Other Short-Term Assets | $3.300M | |
YoY Change | ||
Inventory | $614.0K | |
Prepaid Expenses | ||
Receivables | $1.700M | |
Other Receivables | $0.00 | |
Total Short-Term Assets | $13.53M | |
YoY Change | ||
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $1.665M | |
YoY Change | ||
Goodwill | $12.01M | |
YoY Change | ||
Intangibles | $6.650M | |
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | $0.00 | |
YoY Change | ||
Total Long-Term Assets | $20.47M | |
YoY Change | ||
TOTAL ASSETS | ||
Total Short-Term Assets | $13.53M | |
Total Long-Term Assets | $20.47M | |
Total Assets | $34.00M | |
YoY Change | ||
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $1.741M | |
YoY Change | ||
Accrued Expenses | $5.600M | |
YoY Change | ||
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $0.00 | |
YoY Change | ||
Long-Term Debt Due | $10.43M | |
YoY Change | ||
Total Short-Term Liabilities | $21.21M | |
YoY Change | ||
LONG-TERM LIABILITIES | ||
Long-Term Debt | $8.338M | |
YoY Change | ||
Other Long-Term Liabilities | $5.100M | |
YoY Change | ||
Total Long-Term Liabilities | $8.338M | |
YoY Change | ||
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $21.21M | |
Total Long-Term Liabilities | $8.338M | |
Total Liabilities | $35.46M | |
YoY Change | ||
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$160.6M | |
YoY Change | ||
Common Stock | $1.000K | |
YoY Change | ||
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | -$150.9M | |
YoY Change | ||
Total Liabilities & Shareholders Equity | $34.00M | |
YoY Change |
Cashflow Statement
Concept | 2014 Q2 | 2013 Q2 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | $877.0K | -$802.0K |
YoY Change | -209.35% | |
Depreciation, Depletion And Amortization | $110.0K | $170.0K |
YoY Change | -35.29% | |
Cash From Operating Activities | $850.0K | -$350.0K |
YoY Change | -342.86% | |
INVESTING ACTIVITIES | ||
Capital Expenditures | -$140.0K | -$40.00K |
YoY Change | 250.0% | |
Acquisitions | ||
YoY Change | ||
Other Investing Activities | -$380.0K | $0.00 |
YoY Change | ||
Cash From Investing Activities | -$520.0K | -$40.00K |
YoY Change | 1200.0% | |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 2.700M | -10.00K |
YoY Change | -27100.0% | |
NET CHANGE | ||
Cash From Operating Activities | 850.0K | -350.0K |
Cash From Investing Activities | -520.0K | -40.00K |
Cash From Financing Activities | 2.700M | -10.00K |
Net Change In Cash | 3.030M | -400.0K |
YoY Change | -857.5% | |
FREE CASH FLOW | ||
Cash From Operating Activities | $850.0K | -$350.0K |
Capital Expenditures | -$140.0K | -$40.00K |
Free Cash Flow | $990.0K | -$310.0K |
YoY Change | -419.35% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2014Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
11792746 | shares |
CY2014Q2 | us-gaap |
Embedded Derivative Fair Value Of Embedded Derivative Net
EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet
|
200000 | |
CY2013Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
4485000 | |
CY2014Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
1012959 | shares |
CY2014Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
1012959 | shares |
CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
899950 | shares |
CY2014Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
10000000 | shares |
CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
7.22 | |
CY2014Q2 | us-gaap |
Temporary Equity Shares Issued
TemporaryEquitySharesIssued
|
6043808 | shares |
CY2014Q2 | us-gaap |
Share Price
SharePrice
|
11.44 | |
CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
7.22 | |
CY2014Q2 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
7501370 | shares |
CY2014Q2 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
6043808 | shares |
CY2014Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2014Q2 | us-gaap |
Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
|
0.001 | |
CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
0 | shares |
CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
899950 | shares |
CY2014Q2 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
149444000 | |
CY2014Q2 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
1006000 | |
CY2014Q2 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
173000 | |
CY2014Q2 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
3649000 | |
CY2014Q2 | us-gaap |
Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
|
0 | |
CY2014Q2 | us-gaap |
Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
|
156567000 | |
CY2014Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
21214000 | |
CY2014Q2 | us-gaap |
Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
|
100000 | |
CY2014Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
1000 | |
CY2014Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2014Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1741000 | |
CY2014Q2 | us-gaap |
Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
|
808000 | |
CY2014Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-160583000 | |
CY2014Q2 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
10434000 | |
CY2014Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-150910000 | |
CY2014Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
662000 | |
CY2014Q2 | us-gaap |
Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
|
3500000 | |
CY2014Q2 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
8338000 | |
CY2014Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
33997000 | |
CY2014Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
9672000 | |
CY2014Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
890000 | |
CY2014Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
3241000 | |
CY2014Q2 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
674000 | |
CY2014Q2 | us-gaap |
Liabilities
Liabilities
|
35463000 | |
CY2014Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1190000 | |
CY2014Q2 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
1784000 | |
CY2014Q2 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
81000 | |
CY2014Q2 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
2313000 | |
CY2014Q2 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
3526000 | |
CY2014Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
7872000 | |
CY2014Q2 | us-gaap |
Goodwill
Goodwill
|
12005000 | |
CY2014Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1665000 | |
CY2014Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3319000 | |
CY2014Q2 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
147000 | |
CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
3825000 | |
CY2014Q2 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
1725000 | |
CY2014Q2 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
2800000 | |
CY2014Q2 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
261000 | |
CY2014Q2 | us-gaap |
Embedded Derivative Fair Value Of Embedded Derivative Net
EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet
|
100000 | |
CY2014Q2 | us-gaap |
Assets
Assets
|
33997000 | |
CY2014Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
2200000 | |
CY2014Q2 | us-gaap |
Inventory Net
InventoryNet
|
614000 | |
CY2014Q2 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
353000 | |
CY2014Q2 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
6650000 | |
CY2014Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
0 | |
CY2014Q2 | us-gaap |
Assets Current
AssetsCurrent
|
13530000 | |
CY2014Q2 | cdna |
Debt Instrument Refinance Outstanding Amount
DebtInstrumentRefinanceOutstandingAmount
|
120000 | |
CY2014Q2 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
|
532244 | shares |
CY2014Q2 | cdna |
Fair Value Assets Level One To Level Three Transfers Amount
FairValueAssetsLevelOneToLevelThreeTransfersAmount
|
0 | |
CY2014Q2 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
|
606000 | |
CY2014Q2 | cdna |
Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
|
108000 | |
CY2014Q2 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
|
3219000 | |
CY2014Q2 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
|
367706 | shares |
CY2014Q2 | cdna |
Accrued Initial Public Offering Costs
AccruedInitialPublicOfferingCosts
|
1126000 | |
CY2014Q2 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
|
10.32 | |
CY2014Q2 | cdna |
Accrued Over Payments And Refunds
AccruedOverPaymentsAndRefunds
|
183000 | |
CY2014Q2 | cdna |
Accrued Sample Processing Fees
AccruedSampleProcessingFees
|
306000 | |
CY2014Q2 | cdna |
Royalty Revenue Receivable
RoyaltyRevenueReceivable
|
59000 | |
CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5830000 | |
CY2013Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
1010711 | shares |
CY2013Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
1010711 | shares |
CY2013Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
7737226 | shares |
CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.99 | |
CY2013Q4 | us-gaap |
Temporary Equity Shares Issued
TemporaryEquitySharesIssued
|
5155673 | shares |
CY2013Q4 | us-gaap |
Share Price
SharePrice
|
12.40 | |
CY2013Q4 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
6417954 | shares |
CY2013Q4 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
5155673 | shares |
CY2013Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2013Q4 | us-gaap |
Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
|
0.001 | |
CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
332995 | shares |
CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
466965 | shares |
CY2013Q4 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
135202000 | |
CY2013Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
1623000 | |
CY2013Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
145000 | |
CY2013Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
1048000 | |
CY2013Q4 | us-gaap |
Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
|
2804000 | |
CY2013Q4 | us-gaap |
Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
|
137221000 | |
CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
7593000 | |
CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
1000 | |
CY2013Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2013Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
618000 | |
CY2013Q4 | us-gaap |
Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
|
525000 | |
CY2013Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-160156000 | |
CY2013Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
4461000 | |
CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-150673000 | |
CY2013Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
191000 | |
CY2013Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
10914000 | |
CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
9873000 | |
CY2013Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
9482000 | |
CY2013Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
175000 | |
CY2013Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
525000 | |
CY2013Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
80000 | |
CY2013Q4 | us-gaap |
Liabilities
Liabilities
|
25344000 | |
CY2013Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1386000 | |
CY2013Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
1885000 | |
CY2013Q4 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
43000 | |
CY2013Q4 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
0 | |
CY2013Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
0 | |
CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5128000 | |
CY2013Q4 | us-gaap |
Goodwill
Goodwill
|
0 | |
CY2013Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1553000 | |
CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
255000 | |
CY2013Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
147000 | |
CY2013Q4 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
2270000 | |
CY2013Q4 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
0 | |
CY2013Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
230000 | |
CY2013Q4 | us-gaap |
Assets
Assets
|
9873000 | |
CY2013Q4 | us-gaap |
Inventory Net
InventoryNet
|
518000 | |
CY2013Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
288000 | |
CY2013Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
0 | |
CY2013Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
2000 | |
CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
8171000 | |
CY2013Q4 | cdna |
Fair Value Assets Level One To Level Three Transfers Amount
FairValueAssetsLevelOneToLevelThreeTransfersAmount
|
0 | |
CY2013Q4 | cdna |
Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
|
84000 | |
CY2013Q4 | cdna |
Debt Instrument Refinance Outstanding Amount
DebtInstrumentRefinanceOutstandingAmount
|
0 | |
CY2013Q4 | cdna |
Accrued Initial Public Offering Costs
AccruedInitialPublicOfferingCosts
|
0 | |
CY2013Q4 | cdna |
Accrued Over Payments And Refunds
AccruedOverPaymentsAndRefunds
|
215000 | |
CY2013Q4 | cdna |
Accrued Sample Processing Fees
AccruedSampleProcessingFees
|
195000 | |
CY2013Q4 | cdna |
Royalty Revenue Receivable
RoyaltyRevenueReceivable
|
37000 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.13 | ||
us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
0 | shares | |
us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
0 | shares | |
us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-1277000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | pure | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0102 | pure | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
1011116 | shares | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.13 | ||
us-gaap |
Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
|
0 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.4541 | pure | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6288931 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
1011116 | shares | |
us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-2150000 | ||
us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-1106000 | ||
us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | ||
us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
32000 | ||
us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
296000 | ||
us-gaap |
Licenses Revenue
LicensesRevenue
|
267300 | ||
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
42000 | ||
us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
0 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1034000 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-2150000 | ||
us-gaap |
Embedded Derivative Gain On Embedded Derivative
EmbeddedDerivativeGainOnEmbeddedDerivative
|
0 | ||
us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
126000 | ||
us-gaap |
Royalty Revenue
RoyaltyRevenue
|
30000 | ||
us-gaap |
Reimbursement Revenue
ReimbursementRevenue
|
142300 | ||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-10000 | ||
us-gaap |
Revenues
Revenues
|
10438000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
36000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-2150000 | ||
us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
0 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1637000 | ||
us-gaap |
Sales Revenue Services Net
SalesRevenueServicesNet
|
10142000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
38000 | ||
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
415000 | ||
us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
1083000 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
11472000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1848000 | ||
us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
3117000 | ||
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
300000 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-1345000 | ||
us-gaap |
Cost Of Services
CostOfServices
|
4243000 | ||
us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | ||
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | ||
us-gaap |
Other Noncash Income Tax Expense
OtherNoncashIncomeTaxExpense
|
0 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-32000 | ||
us-gaap |
Amortization Of Deferred Leasing Fees
AmortizationOfDeferredLeasingFees
|
125000 | ||
us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-188000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-36000 | ||
us-gaap |
Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
|
0 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | ||
us-gaap |
Amortization Of Deferred Charges
AmortizationOfDeferredCharges
|
-125000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2264000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
506000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
38000 | ||
us-gaap |
Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
|
56000 | ||
us-gaap |
Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
|
593000 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.42 | ||
us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
0 | shares | |
us-gaap |
Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Collaboration and License Revenue</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company recognizes contingent consideration received from the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved, which the Company believes is more consistent with the substance of its performance under its various license and collaboration agreements. The Company did not recognize any milestones during the three months or six month periods ended June 30, 2014 or 2013.</p> </div> | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P8Y2M1D | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
2.56 | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
CareDx, Inc. | ||
dei |
Trading Symbol
TradingSymbol
|
CDNA | ||
us-gaap |
Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
|
The Company considers all highly liquid investments that are readily convertible into cash having maturities at the time of purchase of three months or less to be cash equivalents. | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
1012769 | shares | |
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
12079 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
4.94 | ||
us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y8M12D | ||
us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
0 | shares | |
us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
1033000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
461795 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | pure | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y1M6D | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
14532 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0170 | pure | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
102189 | shares | |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition, (ii) the differences between amounts billed and estimated receipts from payers, (iii) the determination of the accruals for clinical studies, (iv) the determination of refunds to be requested by third-party payers,(v) the fair value of assets and liabilities, (vi) the valuation of warrants to purchase convertible preferred stock,(vii) the determination of fair value of the Company’s common stock, (viii) the contingent consideration in a business acquisition, (ix) the fair value of the embedded derivative associated with the subordinated convertible note, (x) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xi) any impairment of long-lived assets including in-process technology and goodwill and (xii) legal contingencies. Actual results could differ from those estimates.</p> </div> | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2014-06-30 | ||
us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | Segment | |
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
2.96 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
10.46 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2014 | ||
us-gaap |
Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
|
0 | shares | |
us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
|
164000 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.42 | ||
us-gaap |
Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
|
0.00 | pure | |
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
12.40 | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001217234 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.4184 | pure | |
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7812652 | shares | |
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Concentration of Credit Risk</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company is subject to credit risk from its accounts receivable which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers. For the three months ended June 30, 2014 and 2013, approximately 49% and 57%, respectively, of testing revenue was derived from Medicare. For the six months ended June 30, 2014 and 2013, approximately 49% and 55%, respectively, of testing revenue was derived from Medicare. No other payer represented more than 10% of testing revenue for these periods. At June 30, 2014, approximately 72% of accounts receivable were from Medicare. No other payer represented more than 10% of accounts receivable at June 30, 2014.</p> </div> | ||
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
2199 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
1012769 | shares | |
us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
909000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-427000 | ||
us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-1192000 | ||
us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | ||
us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
1827000 | ||
us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
156000 | ||
us-gaap |
Licenses Revenue
LicensesRevenue
|
31200 | ||
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
96000 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-1927000 | ||
us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
376000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-572000 | ||
us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
2552000 | ||
us-gaap |
Embedded Derivative Gain On Embedded Derivative
EmbeddedDerivativeGainOnEmbeddedDerivative
|
118000 | ||
us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
2152000 | ||
us-gaap |
Royalty Revenue
RoyaltyRevenue
|
117000 | ||
us-gaap |
Reimbursement Revenue
ReimbursementRevenue
|
16200 | ||
us-gaap |
Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
|
0 | ||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-163000 | ||
us-gaap |
Revenues
Revenues
|
12700000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
164000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-427000 | ||
us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
0 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-545000 | ||
us-gaap |
Sales Revenue Services Net
SalesRevenueServicesNet
|
12544000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
185000 | ||
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
222000 | ||
us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
0 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
13272000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1512000 | ||
us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
3084000 | ||
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
349000 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
2744000 | ||
us-gaap |
Cost Of Services
CostOfServices
|
4565000 | ||
us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
283000 | ||
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-1500000 | ||
us-gaap |
Other Noncash Income Tax Expense
OtherNoncashIncomeTaxExpense
|
-1500000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
2251000 | ||
us-gaap |
Amortization Of Deferred Leasing Fees
AmortizationOfDeferredLeasingFees
|
15000 | ||
us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
2117000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-540000 | ||
us-gaap |
Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
|
4982000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
5000 | ||
us-gaap |
Amortization Of Deferred Charges
AmortizationOfDeferredCharges
|
-23000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4111000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1123000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
185000 | ||
us-gaap |
Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
|
-196000 | ||
us-gaap |
Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
|
721000 | ||
cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
|
P9Y5M27D | ||
cdna |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised
|
shares | ||
cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
|
P6Y3M | ||
cdna |
Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved
|
|||
cdna |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod
|
14532 | shares | |
cdna |
Share Based Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares Reserved For Available For Issuance
ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedForAvailableForIssuance
|
shares | ||
cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
|
2.69 | ||
cdna |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted During Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedDuringPeriod
|
461795 | shares | |
cdna |
Initial Public Offering Date Of Completion
InitialPublicOfferingDateOfCompletion
|
2014-07-22 | ||
cdna |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExpired
|
12079 | shares | |
cdna |
Description Of Agreement Expected Expiration Year
DescriptionOfAgreementExpectedExpirationYear
|
The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which is expected to occur in late 2014 or early 2015. | ||
CY2013Q2 | cdna |
Upfront Payment In Cash
UpfrontPaymentInCash
|
387500 | |
CY2013Q2 | cdna |
Upfront Payment In Cash
UpfrontPaymentInCash
|
503000 | |
CY2013Q2 | cdna |
Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
|
250000 | |
CY2013Q2 | cdna |
Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
|
344000 | |
CY2013Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-802000 | |
CY2013Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-256000 | |
CY2013Q2 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
21000 | |
CY2013Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
19000 | |
CY2013Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
5713000 | |
CY2013Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
846000 | |
CY2013Q2 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
1548000 | |
CY2013Q2 | us-gaap |
Cost Of Services
CostOfServices
|
2119000 | |
CY2013Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
CY2013Q2 | us-gaap |
Amortization Of Deferred Leasing Fees
AmortizationOfDeferredLeasingFees
|
62500 | |
CY2013Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1200000 | |
CY2014Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.13 | |
CY2013Q3 | us-gaap |
Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
|
467000 | |
CY2013 | us-gaap |
Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
|
0.00 | pure |
CY2012 | us-gaap |
Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
|
1000000 | |
CY2014Q2 | cdna |
Amortization Of Debt Discount
AmortizationOfDebtDiscount
|
51000 | |
CY2013Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.79 | |
CY2013Q2 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
0 | shares |
CY2013Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
0 | shares |
CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | pure |
CY2013Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0102 | pure |
CY2013Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
1011123 | shares |
CY2013Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.79 | |
CY2013Q2 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
|
0 | shares |
CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.4529 | pure |
CY2013Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6288931 | shares |
CY2013Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
1011123 | shares |
CY2013Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-802000 | |
CY2013Q2 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-541000 | |
CY2013Q2 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | |
CY2013Q2 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
124000 | |
CY2013Q2 | us-gaap |
Licenses Revenue
LicensesRevenue
|
104100 | |
CY2013Q2 | us-gaap |
Reimbursement Revenue
ReimbursementRevenue
|
41600 | |
CY2013Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-5000 | |
CY2013Q2 | us-gaap |
Revenues
Revenues
|
5457000 | |
CY2013Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-802000 | |
CY2013Q2 | us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
0 | |
CY2013Q2 | us-gaap |
Sales Revenue Services Net
SalesRevenueServicesNet
|
5333000 | |
CY2014Q2 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
189726 | shares |
CY2014Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
381434 | shares |
CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | pure |
CY2014Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y3M18D | |
CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0174 | pure |
CY2014Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
6939568 | shares |
CY2014Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.87 | |
CY2014Q2 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
|
5355280 | shares |
CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.4218 | pure |
CY2014Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1092966 | shares |
CY2014Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
1013128 | shares |
CY2014Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
892000 | |
CY2014Q2 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-644000 | |
CY2014Q2 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | |
CY2014Q2 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
66000 | |
CY2014Q2 | us-gaap |
Licenses Revenue
LicensesRevenue
|
1800 | |
CY2014Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-623000 | |
CY2014Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-345000 | |
CY2014Q2 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
59000 | |
CY2014Q2 | us-gaap |
Reimbursement Revenue
ReimbursementRevenue
|
1800 | |
CY2014Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
366000 | |
CY2014Q2 | us-gaap |
Revenues
Revenues
|
6776000 | |
CY2014Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
877000 | |
CY2014Q2 | us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
15000 | |
CY2014Q2 | us-gaap |
Sales Revenue Services Net
SalesRevenueServicesNet
|
6710000 | |
CY2014Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
137000 | |
CY2014Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
7121000 | |
CY2014Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
792000 | |
CY2014Q2 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
1610000 | |
CY2014Q2 | us-gaap |
Cost Of Services
CostOfServices
|
2403000 | |
CY2014Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-1500000 | |
CY2014Q2 | us-gaap |
Amortization Of Deferred Leasing Fees
AmortizationOfDeferredLeasingFees
|
0 | |
CY2014Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2316000 |